CA9hu-1 / Mabpro - LARVOL DELTA

CAMP1: Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours (clinicaltrials.gov) - P1 | N=50 | Not yet recruiting | Sponsor: Mabpro, a.s. | Trial completion date: Jan 2026 ➔ Jan 2027 | Initiation date: Jan 2023 ➔ Jan 2024 | Trial primary completion date: Jan 2025 ➔ Jan 2026

Metastases • Trial completion date • Trial initiation date • Trial primary completion date • Breast Cancer • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer • CA9

CAMP1: Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours (clinicaltrials.gov) - P1 | N=50 | Not yet recruiting | Sponsor: Mabpro, a.s.

Metastases • New P1 trial • Breast Cancer • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer • CA9